Welcome, Guest. Please login or register.
July 13, 2024, 11:52:04 pm

Login with username, password and session length


Members
Stats
  • Total Posts: 55130
  • Total Topics: 4851
  • Online Today: 103
  • Online Ever: 1314
  • (June 22, 2016, 05:23:42 am)
Users Online
Users: 0
Guests: 40
Total: 40

Welcome

Welcome to the Hep Forums, a round-the-clock discussion area for people who have Fatty Liver Disease, Hepatitis B, C or a co-infection, their friends and family and others with questions about hepatitis and liver health. Check in frequently to read what others have to say, post your comments, and hopefully learn more about how you can reach your own health goals.

Privacy Warning: Please realize that these forums are open to all, and are fully searchable via Google and other search engines. If this concerns you, then do not use a username or avatar that are self-identifying in any way. We do not allow the deletion of anything you post in these forums, so think before you post.
  • The information shared in these forums, by moderators and members, is designed to complement, not replace, the relationship between an individual and his/her own physician.
  • All members of these forums are, by default, not considered to be licensed medical providers. If otherwise, users must clearly define themselves as such.
  • Product advertisement (including links); banners; and clinical trial, study or survey participation—is strictly prohibited by forums members unless permission has been secured from the Hep Forum Moderators.
Finished Reading This? You can collapse this or any other box on this page by clicking the symbol in each box.

Author Topic: FDA OK’s Harvoni and Sovaldi for Hepatitis C Treatment in Adolescents  (Read 5645 times)

0 Members and 1 Guest are viewing this topic.

Offline Hep Editors

  • Member
  • Posts: 784
    • Hep Mag
The FDA has approved the use of Gilead Sciences’ Harvoni (ledipasvir/sofosbuvir) and Sovaldi to treat hepatitis C virus (HCV) in 12- to 17-year-olds, MedPage Today reports. This is the first approval of direct-acting antivirals (DAAs) to treat hep C among the pediatric population.

Harvoni and Sovaldi are both already approved for adult use.

According to the Centers for Disease Control and Prevention, an estimated 23,000 to 46,000 children are living with hep C in the United States, most of whom contracted the virus from their mothers at birth.

Read more...
https://www.hepmag.com/article/fda-oks-harvoni-sovaldi-hepatitis-c-treatment-adolescents

Offline FutureThinker

  • Member
  • Posts: 711
  • Onward and upward!
This is great news -- as we all know, the sooner one can get this virus out of their system, the better!!  FT
Treatment naive
Likely contracted mid-70s
Diagnosed 1a, 2011
F1-2
Harvoni X 12 weeks, completed 5/17/16
Pre-treatment: VL 3 mil, AST 64, ALT 84
4 week labs: VL 30, AST 21, ALT 14
8 week labs: VL UD!!!, AST 22, ALT 16
12 week labs: VL UD, AST 23, ALT 14
2 wk EOT: VL UD
12 wk EOT: VL UD, AST 22, ALT 13 =  SVR 12! Yay! 
Last hep appointment: VL UD, AST 19, ALT 12 = SVR 39! I AM DONE!

 


© 2024 Smart + Strong. All Rights Reserved.   terms of use and your privacy
Smart + Strong® is a registered trademark of CDM Publishing, LLC.